Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Pesaran

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
JCO Precision Oncology|February 17, 2022
<i>PTEN</i> Promoter Variants Are Not Associated With Common Cancers: Implications for Multigene Panel TestingMary Helen Black, Shuwei Li, Tina Pesaran, et al.
Cancer Genetics|September 23, 2020
Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testingCristina Fortuno, Tina Pesaran, Jessica Mester, et al.
Human Mutation|January 4, 2020
Differences in patient ascertainment affect the use of gene-specified ACMG/AMP phenotype-related variant classification criteria: Evidence for TP53Cristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Cancer Genetics|July 13, 2019
p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patientsCristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Efforts Toward Consensus Variant Interpretation by Commercial LaboratoriesJill S Dolinsky, Kathleen S Hruska, Tina Pesaran, et al.
Human Mutation|July 10, 2021
Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancerSharon E Johnatty, Tina Pesaran, Jill Dolinsky, et al.
Human Mutation|May 19, 2018
Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variantsCristina Fortuno, Paul A James, Erin L Young, et al.
Human Mutation|September 8, 2018
Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterionAhmad N Abou Tayoun, Tina Pesaran, Marina T DiStefano, et al.
The Journal of Molecular Diagnostics : JMD|July 14, 2015
Processed Pseudogene Confounding Deletion/Duplication Assays for SMAD4Alison Millson, Tracey Lewis, Tina Pesaran, et al.
Human Mutation|July 17, 2021
An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategyCristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
JCO Precision Oncology|February 17, 2022
<i>PTEN</i> Promoter Variants Are Not Associated With Common Cancers: Implications for Multigene Panel TestingMary Helen Black, Shuwei Li, Tina Pesaran, et al.
Cancer Genetics|September 23, 2020
Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testingCristina Fortuno, Tina Pesaran, Jessica Mester, et al.
Human Mutation|January 4, 2020
Differences in patient ascertainment affect the use of gene-specified ACMG/AMP phenotype-related variant classification criteria: Evidence for TP53Cristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Cancer Genetics|July 13, 2019
p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patientsCristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Efforts Toward Consensus Variant Interpretation by Commercial LaboratoriesJill S Dolinsky, Kathleen S Hruska, Tina Pesaran, et al.
Human Mutation|July 10, 2021
Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancerSharon E Johnatty, Tina Pesaran, Jill Dolinsky, et al.
Human Mutation|May 19, 2018
Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variantsCristina Fortuno, Paul A James, Erin L Young, et al.
Human Mutation|September 8, 2018
Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterionAhmad N Abou Tayoun, Tina Pesaran, Marina T DiStefano, et al.
The Journal of Molecular Diagnostics : JMD|July 14, 2015
Processed Pseudogene Confounding Deletion/Duplication Assays for SMAD4Alison Millson, Tracey Lewis, Tina Pesaran, et al.
Human Mutation|July 17, 2021
An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategyCristina Fortuno, Tina Pesaran, Jill Dolinsky, et al.
Pageof 9